ArticleCureus2026
Bioavailability-Enhanced Curcumin (CurcuBoost®) as Adjunct Therapy Improves Symptoms in Knee Osteoarthritis: A Randomized Clinical Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives This study aimed to evaluate the efficacy, safety, and tolerability of the bioavailability-enhanced curcumin formulation CurcuBoost® as an adjunct to standard of care (SOC) in subjects with knee osteoarthritis (OA). Methods In this randomized, open-label, parallel-group trial, adults aged 40-75 years with radiographically confirmed knee OA (Kellgren-Lawrence grade II-III) were randomized (1:1) to receive CurcuBoost® 500 mg once daily + SOC or SOC alone for eight weeks. Analyses were conducted in the modified intention-to-treat (mITT) population. Results All 50 participants completed the study. At week 8, CurcuBoost® + SOC resulted in significantly greater reductions in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain compared with SOC alone (mean ± SD: 4.68 ± 1.65 vs 7.40 ± 2.18; p < 0.0001), corresponding to a 65.2% versus 44.0% reduction from baseline. Significant improvements favoring CurcuBoost® were also observed in WOMAC physical function (-59.1% vs -38.9%; p < 0.0001), WOMAC total score (-59.9% vs -40.7%; p < 0.0001), and Visual Analog Scale (VAS) pain score (-61.5% vs -39.5%; p < 0.0001). Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) responder rates at week 8 were higher with CurcuBoost® (80% (n = 20) vs 48% (n = 12); p = 0.0184). Improvements in the EuroQol 5-Dimension questionnaire (EQ-5D) and global assessments were also significantly greater (all p < 0.01) in the CurcuBoost® + SOC group. No treatment-related serious adverse events (SAEs) were reported. Conclusion CurcuBoost® as an adjunct to SOC significantly improved pain, function, and quality of life in knee OA with a favorable safety profile, supporting its role as an effective complementary therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.